GlassScriptPhysician profile
Kimball W Silverton
NPI 1013924570
$5,769.49
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,582 · 2020: $1,682 · 2021: $1,436 · 2022: $69.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,002.35 | 2019-2021 | |
| Janssen Biotech, INC. | $623.46 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $519.53 | 2019-2021 | |
| Amgen INC. | $466.51 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $353.73 | 2019-2020 | |
| Genzyme Corporation | $261.73 | 2019-2021 | |
| Lilly USA, LLC | $245.62 | 2019-2021 | |
| Pfizer INC. | $187.62 | 2019-2021 | |
| Celgene Corporation | $161.56 | 2019 | |
| Galderma Laboratories, L.P. | $152.35 | 2020 | |
| Allergan, INC. | $128.81 | 2019-2022 | |
| Ucb, INC. | $120.00 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $103.43 | 2020 | |
| Genentech USA, INC. | $66.03 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $38.69 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $37.97 | 2020 | |
| Leo Pharma INC. | $28.81 | 2020-2021 | |
| Aclaris Therapeutics, INC. | $23.84 | 2019 | |
| Biofrontera INC. | $20.40 | 2019 | |
| Epi Health, LLC | $18.93 | 2020 | |
| Promius Pharma LLC | $15.66 | 2019 | |
| Dermira, INC. | $15.50 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimball Silverton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.